Hjem › Akut myeloid leukæmi › Arkansas
Akut myeloid leukæmi kliniske forsøg i Arkansas
13 studier for Akut myeloid leukæmi søger deltagere på steder i Arkansas.
Byer i Arkansas
Officiel studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Fort Smith, Fort Smith
- CARTI Cancer Center, Little Rock
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- University of Arkansas at Little Rock, Little Rock
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Arkansas for Medical Sciences, Little Rock
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Arkansas for Medical Sciences, Little Rock
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Arkansas Children's Hospital, Little Rock
RekruttererFase 3
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Arkansas Children's Hospital, Little Rock
RekruttererFase 3
Alder 1 til 25 · Alle køn · Opdateret 4. sep. 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Arkansas Children's Hospital, Little Rock
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Arkansas Children's Hospital, Little Rock
RekruttererFase 3
29 Days – 21 Years · Alle køn · Opdateret 24. aug. 2026 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Arkansas Children's Hospital, Little Rock
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Arkansas Children's Hospital, Little Rock
RekruttererFase 1
Op til 21 år · Alle køn · Opdateret 22. apr. 2026 · NCT05101551Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.